MiMedx Group is trading at $4.05 (6.7% down) as investors digest its second-quarter earnings and the announced acquisition of Sanara MedTech.
- The company reported a sharp year-over-year revenue decline tied to Medicare reimbursement changes in its wound segment, partially offset by growth in surgical products.
- Management reaffirmed its 2026 guidance, though the sizable Sanara deal and ongoing regulatory headwinds in wound care appear to be driving a cautious market response.